Skip to content
sellWeak cluster of 210b5-1 plan

Joseph Michael Fitzgerald sold $5.0M of BSX

EVP & Group Pres, Cardiology at BOSTON SCIENTIFIC CORP. 50,000 shares at an average of $99.47, traded Nov 3, 2025, filed Nov 4, 2025.

Warning score
18
Value
$5.0M
50,000 shares
Holdings after
178,342
-22% from before
From 52-week low
+16%
low $84.72, close $98.59
From 52-week high
-9%
high $108.14, as of Nov 3, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $5.0M at market
    +25
  • Share of holdings sold
    Sold 22% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -1.1%, 3m -7.3%, 6m -43.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BSXOct 9, 2026 · close 42.73
Since filing Nov 4, 2025: -56.8%SPY +16.5% · excess -73.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001225208-25-008911, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 3, 2025MOption exercise
Common Stock10b5-1
+50,000$26.15$1.3M228,342Nov 4, 2025
Nov 3, 2025SOpen-market sale
Common Stock10b5-1
-3,600$100.75$363k224,742Nov 4, 2025
Nov 3, 2025SOpen-market sale
Common Stock10b5-1
-16,928$99.76$1.7M207,814Nov 4, 2025
Nov 3, 2025SOpen-market sale
Common Stock10b5-1
-29,472$99.14$2.9M178,342Nov 4, 2025
Nov 3, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-50,000$0.00$00Nov 4, 2025

Related signals

Other insiders at BOSTON SCIENTIFIC CORP and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
BSXbuy
BOSTON SCIENTIFIC CORP
Susan E Morano
director
$100k
2,040 shares
+17%
56Moderate
BSXbuy 3
BOSTON SCIENTIFIC CORP
David C Habiger
director
$100k
2,100 shares
+14%
76Notable
BSXbuy 3
BOSTON SCIENTIFIC CORP
Michael F Mahoney
Chairman, President & CEO
$9.0M
186,240 shares
+13%
53Moderate
BSXbuy 3
BOSTON SCIENTIFIC CORP
David C Habiger
director
$57k
1,182 shares
+9%
69Notable
BSXbuy 3
BOSTON SCIENTIFIC CORP
Edward J Ludwig
director
$227k
5,000 shares
+20%
67Notable
BSXbuy 3
BOSTON SCIENTIFIC CORP
David C Habiger
director
$251k
4,450 shares
+47%
63Notable
BSXbuy 3
BOSTON SCIENTIFIC CORP
Edward J Ludwig
director
$203k
3,580 shares
+16%
66Notable
BSXbuy 3
BOSTON SCIENTIFIC CORP
Cheryl Pegus
director
$100k
1,770 shares
-
20Weak
BSXsell10b5-1
BOSTON SCIENTIFIC CORP
Michael F Mahoney
Chairman, President & CEO
$15M
160,901 shares
-10%
25Weak
BSXsell10b5-1
BOSTON SCIENTIFIC CORP
Arthur C Butcher
EVP& Grp Pres, MedSurg & APAC
$1.8M
17,313 shares
-42%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joseph Michael Fitzgerald sold $5.0M of BSX | InsiderTell